What 2023 Holds for Cell and Gene Therapy

What 2023 Holds
As we look ahead to 2023, the field of cell and gene therapy is on the brink of some major developments and milestones.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Accelerating Biology: New Product Innovations from 10x Genomics

10x Genomics

Multicellular organisms and dynamic biological processes consist of a complex and coordinated interplay of multiple individual cells. Until recently, most molecular studies have relied on bulk analysis, combining all cells into a single average readout. In recent years, single-cell RNA sequencing technologies have enabled researchers to study development and disease at the level of individual cells, revealing cell-to-cell gene expression differences that were obscured with bulk or low throughput methods.
Watch Now

Capturing Signaling Patterns through Global Phosphorylation Profiling and Intracellular Flow Cytometry

Comparenetworks

Signals are given in contexts such as mate selection by females, which subjects the advertising males' signals to selective pressure. Signals thus evolve because they modify the behaviour of the receiver to benefit the signaller. Signals may be honest, conveying information which usefully increases the fitness of the receiver, or dishonest. An individual can cheat by giving a dishonest signal, which might briefly benefit that signaller, at the risk of undermining the signalling system for the whole population.
Watch Now

The Evolving Role of BRCA Testing in Ovarian Cancer

captodayonline

Webinar presenters Dana Chase, MD, FACOG,Assistant Professor, Division of Gynecologic Oncology University of Arizona College of Medicine, Phoenix, AZ, Creighton University School of Medicine at St. Joseph’s Hospital, Phoenix, AZ, Gynecologic Oncologist, Arizona Oncology, and John Longshore, PhD, FACMG, Director, Molecular Pathology, Carolinas Pathology Group, Carolinas HealthCare System, Charlotte, North Carolina, discuss the link between molecular profiles and disease pathogenesis in ovarian cancer, the clinical significance of PARP inhibition in BRCA1 and/or 2–mutated ovarian cancer, the testing process for BRCA mutations, and the evolving paradigms in tumor and germline BRCA testing in ovarian cancer.
Watch Now

2019 Joint Commission National Patient Safety Goals: Update and Practical Advice

Lorman Education Services

Understand the update of the National Patient Safety Goals to be sure your organization is in compliance with the requirements. Each year healthcare providers must meet the requirements of the Joint Commission's National Patient Safety Goals as part of the accreditation process. Receive an overview and update of the 2019 National Patient Safety Goals. Receive practical advice to implement the goals. Failing to meet a requirement will result in a requirement for improvement. This information is critical to ensure you are aware of the requirements.
Watch Now

Spotlight

resources